MARKET

XENE

XENE

Xenon Pharmaceut
NASDAQ
38.98
+0.46
+1.19%
After Hours: 38.98 0 0.00% 16:00 01/21 EST
OPEN
38.83
PREV CLOSE
38.52
HIGH
40.04
LOW
38.56
VOLUME
340.91K
TURNOVER
--
52 WEEK HIGH
50.99
52 WEEK LOW
35.53
MARKET CAP
2.97B
P/E (TTM)
-13.8778
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at XENE last week (0113-0117)?
Weekly Report · 2d ago
Xenon Pharmaceuticals’ CCO Departure and Consultancy Role
TipRanks · 4d ago
BUZZ-Jefferies raises PT on Xenon Pharmaceuticals
Reuters · 5d ago
XENON PHARMACEUTICALS INC <XENE.O>: JEFFERIES RAISES TARGET PRICE TO $65 FROM $60
Reuters · 6d ago
Xenon Pharmaceuticals: 2025 Could Be Pivotal For Azetukalner's Epilepsy Potential
Seeking Alpha · 6d ago
Xenon Pharmaceuticals Sets Sights on Key 2025 Milestones
TipRanks · 01/13 14:11
Xenon Pharmaceuticals outlines key corporate milestone opportunities for 2025
TipRanks · 01/13 14:01
Weekly Report: what happened at XENE last week (0106-0110)?
Weekly Report · 01/13 10:21
More
About XENE
Xenon Pharmaceuticals Inc. is a Canada-based neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing therapeutics to improve the lives of people living with neurological and psychiatric disorders. The Company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, the Company's lead Kv7 channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. Azetukalner is being developed for the treatment of epilepsy, including focal onset seizures (FOS) and primary generalized tonic-clonic seizures (PGTCS) as well as major depressive disorder (MDD). The Company is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications. It has an ongoing collaboration with Neurocrine Biosciences, Inc. to develop treatments for epilepsy.

Webull offers Xenon Pharmaceuticals Inc stock information, including NASDAQ: XENE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XENE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XENE stock methods without spending real money on the virtual paper trading platform.